Stocktoria

Zhengye Biotechnology Holding Ltd ZYBT

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2025-01-07

Zhengye Biotechnology Holding Ltd statistics & valuation

Profitability & efficiency

Net margin (%)
14.90% 0.80% -60.00% 202320242025
Gross margin (%)
55.50% 6.70% 20.50% 202320242025
Operating margin (%)
21.30% 1.20% -60.60% 202320242025
Return on equity (%)
9.30% 3.20% -22.80% 202320242025
Shares outstanding
45.7M 45.7M 47.4M 202320242025
Net debt ($)
-$5.1M -$906000 $1.4M 202320242025
Share buybacks ($)
202320242025
Return on assets (%)
6.30% 2.30% -16.00% 202320242025
Free cash flow margin (%)
19.30% 2.00% 10.60% 202320242025
Debt / equity (×)
0.03× 0.03× 0.03× 202320242025
EPS ($)
$0.69 $0.03 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Gross margin20.5%6.7%55.5%
Operating margin-60.6%1.2%21.3%
Net margin-60.0%0.8%14.9%
FCF margin10.6%2.0%19.3%
Return on assets-16.0%2.3%6.3%
Return on equity-22.8%3.2%9.3%
Debt / equity0.03×0.03×0.03×
Current ratio1.141.311.26

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.